Houda Alachkar, assistant professor of clinical pharmacy at the USC School of Pharmacy, was awarded a five-year, $1.79 million National Institutes of Health (NIH) grant to fund a study that could lead to advancements in the development of personalized treatments for acute myeloid leukemia.
The project is entitled “Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia.”
“This grant will support my lab’s efforts to advance the development of personalized treatments for acute myeloid leukemia patients,” Alachkar says. “We will leverage genomic and immunogenomic data obtained from patients undergoing stem cell transplantation to identify leukemia-specific neoantigens for preclinical investigation as potential therapeutic targets.”